ANI PHARMACEUTICALS, INC: 10-Q filed 2013-05-10
What ANI PHARMACEUTICALS, INC reported in its quarterly report filed 2013-05-10 (fiscal Q1 2013): 17 published measures, 34 facts as tagged in accession 0001104659-13-040291.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2013-05-10
- Fiscal period
- fiscal Q1 2013
- Accession
- 0001104659-13-040291 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ANI PHARMACEUTICALS, INC filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | 35,356,386 | USD | |
| At 2012-12-31 | 38,769,170 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | 9,325,736 | USD | |
| At 2012-12-31 | 10,593,665 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | 26,030,650 | USD | |
| At 2012-12-31 | 28,175,505 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | 29,388,772 | USD | |
| At 2012-12-31 | 34,794,341 | USD | |
| At 2012-03-31 | 49,473,732 | USD | |
| At 2011-12-31 | 57,225,234 | USD |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | 54,234 | USD | 91 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-03-31 | 145,040 | USD | 90 |
| 2012-01-01 to 2012-03-31 | 114,000 | USD | 91 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | -247,247,536 | USD | |
| At 2012-12-31 | -244,956,887 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-12-31 | 166,386 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-03-31 | 145,794 | USD | 90 |
| 2012-01-01 to 2012-03-31 | 313,027 | USD | 91 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | 31,926,746 | USD | |
| At 2012-12-31 | 35,173,144 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-03-31 | 64,671 | USD | 90 |
| 2012-01-01 to 2012-03-31 | 124,196 | USD | 91 |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | 164,352 | USD | |
| At 2012-12-31 | 1,128,644 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-03-31 | 972,049 | USD | 90 |
| 2012-01-01 to 2012-03-31 | 5,183,217 | USD | 91 |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | 277,874 | USD | |
| At 2012-12-31 | 378,803 | USD |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-03-31 | -2,290,649 | USD | 90 |
| 2012-01-01 to 2012-03-31 | -10,264,477 | USD | 91 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-03-31 | 1,949,114 | USD | 90 |
| 2012-01-01 to 2012-03-31 | 1,831,852 | USD | 91 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-03-31 | 166,386 | USD | 90 |
| 2012-01-01 to 2012-03-31 | 30,866 | USD | 91 |
Inspect the source
- Entity
- ANI PHARMACEUTICALS, INC / CIK 0001023024
- Captured
- 2026-09-20T05:13:47.462Z
- SEC response SHA-256
73f151e92444492f6e76683dd14e436bd7ae49ff3f0c015ea516484800094ee5
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001023024.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))